The DOI matches its Crossref record; 241 of the 242 references it cites were found in a registry or an index.
Mesenchymal stromal cell therapies: immunomodulatory properties and clinical progress
Open accessAbstract
Mesenchymal stromal cells (MSCs) are a subset of heterogeneous non-hematopoietic fibroblast-like cells that can differentiate into cells of multiple lineages, such as chondrocytes, osteoblasts, adipocytes, myoblasts, and others. These multipotent MSCs can be found in nearly all tissues but mostly located in perivascular niches, playing a significant role in tissue repair and regeneration. Additionally, MSCs interact with immune cells both in innate and adaptive immune systems, modulating immune responses and enabling immunosuppression and tolerance induction. Understanding the biology of MSCs and their roles in clinical treatment is crucial for developing MSC-based cellular therapy for a variety of pathological conditions. Here, we review the progress in the study on the mechanisms underlying the immunomodulatory and regenerative effects of MSCs; update the medical translation of MSCs, focusing on the registration trials leading to regulatory approvals; and discuss how to improve therapeutic efficacy and safety of MSC applications for future.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures



Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“MSCs, self-renewing multipotent stromal cells, can differentiate into many cell types, including hepatocyte-like cells.”
From From signaling pathways to clinical trials: mesenchymal stem cells as multimodal regenerative architects in liver cirrhosis therapy (2025) · cites this paper as [37]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The cells possess two distinctive properties: the ability to self-renew in their undifferentiated form and the ability to differentiate into multiple cell lineages [37, 38].”
From From signaling pathways to clinical trials: mesenchymal stem cells as multimodal regenerative architects in liver cirrhosis therapy (2025) · cites this paper as [37]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Mesenchymal stem cells are multi-potential stromal cells found in the majority of tissues, including bone marrow(BM), umbilical cord (UC) blood, fat, and amniotic fluid (AF).”
From From signaling pathways to clinical trials: mesenchymal stem cells as multimodal regenerative architects in liver cirrhosis therapy (2025) · cites this paper as [37]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Multilineage potential of adult human mesenchymal stem cells
Pittenger, M. F., Mackay, A. M., Beck, S. C., Jaiswal, R. K., Douglas, R., Mosca, J. D., Moorman, M. A., Simonetti, D. W., Craig, S., & Marshak, D. R. (1999) · Science · doi:10.1126/science.284.5411.143 · Cited by 21,052 · cited 1×
“established that human bone marrow (BM) also contains a subpopulation of stromal cells exhibiting trilineage mesenchymal potential, differentiating into adipocytes, chondroblasts, and osteoblasts under defined condition in vitro [7].”
BackgroundDominici, M., Le Blanc, K., Mueller, I., Slaper-Cortenbach, I., Marini, F. C., Krause, D. S., Deans, R. J., Keating, A., Prockop, D. J., & Horwitz, E. M. (2006) · Cytotherapy · doi:10.1080/14653240600855905 · Cited by 17,766
Caplan, A. I. (1991) · Journal of Orthopaedic Research · doi:10.1002/jor.1100090504 · Cited by 6,548
The chemokine system in diverse forms of macrophage activation and polarization
MANTOVANI, A., SICA, A., SOZZANI, S., ALLAVENA, P., VECCHI, A., & LOCATI, M. (2004) · Trends in Immunology · doi:10.1016/j.it.2004.09.015 · Cited by 6,534
Afshin, A., Sur, P. J., Fay, K. A., Cornaby, L., Ferrara, G., Salama, J. S., Mullany, E. C., Abate, K. H., Abbafati, C., Abebe, Z., et al. (2019) · The Lancet · doi:10.1016/s0140-6736(19)30041-8 · Cited by 5,811
Human mesenchymal stem cells modulate allogeneic immune cell responses
Aggarwal, S., & Pittenger, M. F. (2005) · Blood · doi:10.1182/blood-2004-04-1559 · Cited by 4,511
A perivascular origin for mesenchymal stem cells in multiple human organs
Crisan, M., Yap, S., Casteilla, L., Chen, C.-W., Corselli, M., Park, T. S., Andriolo, G., Sun, B., Zheng, B., Zhang, L., et al. (2008) · Cell Stem Cell · doi:10.1016/j.stem.2008.07.003 · Cited by 3,991 · cited 1×
“perivascular pericytes [17, 18], which markedly diversifying the study and application of MSCs.”
BackgroundMesenchymal stem cells in health and disease
Uccelli, A., Moretta, L., & Pistoia, V. (2008) · Nature Reviews Immunology · doi:10.1038/nri2395 · Cited by 3,746 · cited 4×
“Very importantly, fail-safe mechanism exists in MSCs’ actions, preventing excessive inhibition of T cell responses and host being vulnerable to infectious agents [11, 119].”
BackgroundInfluentialJohnson, C. O., Nguyen, M., Roth, G. A., Nichols, E., Alam, T., Abate, D., Abd-Allah, F., Abdelalim, A., Abraha, H. N., Abu-Rmeileh, N. M., et al. (2019) · The Lancet Neurology · doi:10.1016/s1474-4422(19)30034-1 · Cited by 3,264
Di Nicola, M., Carlo-Stella, C., Magni, M., Milanesi, M., Longoni, P. D., Matteucci, P., Grisanti, S., & Gianni, A. M. (2002) · Blood · doi:10.1182/blood.v99.10.3838 · Cited by 3,226 · cited 4×
“It has been demonstrated that in vitro T lymphocyte proliferation induced by polyclonal mitogens, allogeneic cells, or specific antigen can be considerably inhibited by MSCs. MSCs are capable of promoting apoptosis of activated T cells via the Fas/Fas ligand pathway [111], as well as constitutively secreting inhibitor…”
BackgroundInfluential
Research works printed but not linked: 2
- Klyushnenkova E, Mosca JD, McIntosh KR, Thiede MA. Human mesenchymal stem cells suppress allogeneic T cell responses in vitro: implications for allogeneic transplantation [abstract]. Blood. 1998;92:642a.
- Cojocaru M, Cojocaru IM, Silosi I, Vrabie CD. Manifestations of systemic lupus erythematosus. Maedica. 2011;6:330–6.
Cited by
Improving head and neck cancer therapies by immunomodulation of the tumour microenvironment
Ruffin, A. T., Li, H., Vujanovic, L., Zandberg, D. P., Ferris, R. L., & Bruno, T. C. (2023) · Nature Reviews Cancer · doi:10.1038/s41568-022-00531-9 · Cited by 305
Mesenchymal stem cells and their microenvironment
Liu, J., Gao, J., Liang, Z., Gao, C., Niu, Q., Wu, F., & Zhang, L. (2022) · Stem Cell Research & Therapy · doi:10.1186/s13287-022-02985-y · Cited by 236
“They are widely used in cell therapy, tissue engineering and regenerative medicine for their self-renewal, pluripotency and immunomodulatory properties [3, 4].”
BackgroundMesenchymal stem cells in treating human diseases: molecular mechanisms and clinical studies
Han, X., Liao, R., Li, X., Zhang, C., Huo, S., Qin, L., Xiong, Y., He, T., Xiao, G., & Zhang, T. (2025) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-025-02313-9 · Cited by 227
Immunomodulatory strategies for bone regeneration: A review from the perspective of disease types
Su, N., Villicana, C., & Yang, F. (2022) · Biomaterials · doi:10.1016/j.biomaterials.2022.121604 · Cited by 179
Recent advances to enhance the immunomodulatory potential of mesenchymal stem cells
Sarsenova, M., Kim, Y., Raziyeva, K., Kazybay, B., Ogay, V. B., & Saparov, A. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.1010399 · Cited by 136
Metadata
- Authors
- Wu, X., Jiang, J., Gu, Z., Zhang, J., Chen, Y., & Liu, X.
- Affiliations
- University of Basel (CH)
- Fuzhou Dermatosis Prevention Hospital (CN)
- Fudan University (CN)
- Fujian Medical University (CN)
- Corresponding author
- Chen, Yang
- Liu, Xiaolong
- Venue
- Stem Cell Research & Therapy
- Published
- 2020-08-08
- Volume
- 11
- Issue
- 1
- Pages
- 345-345
- ISSN
- 1757-6512 (ISSN-L)
- PMC
- PMC7414268
- OpenAlex
- W3047744932
- Semantic Scholar
- 15d07be05f6ef52a4d64f181441d8da3647cc210
- Cited by
- 343
- References
- 242
- Citations by year
- 2026: 41 · 2025: 70 · 2024: 72 · 2023: 59 · 2022: 55 · 2021: 41 · 2020: 5
- FWCI
- 5.88
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- cc-by
- creativecommons.org/licenses/by/4.0 (tdm)
- creativecommons.org/licenses/by/4.0 (vor)
- Locations
- Stem Cell Research & Therapy (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Funders
- the science foundation of Fuzhou (2019-S-95)
- the Key Clinical Specialty Discipline Construction Program of Fuzhou (201807111)
- the Clinical Medicine Center Construction Program of Fuzhou (2018080309)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cell Biology › Mesenchymal stem cell research
- Health Sciences › Dentistry › Periodontics › Periodontal Regeneration and Treatments
- Health Sciences › Medicine › Hematology › Hematopoietic Stem Cell Transplantation
- Keywords
- mesenchymal stem cells, immunomodulation, immunosuppression, tolerance induction, tissue regeneration, multipotency, perivascular niche, clinical translation, regulatory approval, clinical trials, treatment safety
- MeSH terms
- Cell Differentiation, Immunity, Mesenchymal Stem Cell Transplantation, Immunomodulation, Mesenchymal Stem Cells, Cell- and Tissue-Based Therapy
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Mesenchymal stromal cell therapies: immunomodulatory properties and clinical progress. https://app.cochat.ai/papers/10.1186/s13287-020-01855-9
- The paper
- Wu, X., Jiang, J., Gu, Z., Zhang, J., Chen, Y., & Liu, X. (2020). Mesenchymal stromal cell therapies: immunomodulatory properties and clinical progress. Stem Cell Research & Therapy. https://doi.org/10.1186/s13287-020-01855-9
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.